Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Change in Accured Expenses data on record, last reported at $708000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 895.51% year-over-year to $708000.0; the TTM value through Sep 2025 reached $1.5 million, up 537.79%, while the annual FY2024 figure was -$245000.0, 93.15% up from the prior year.
  • Change in Accured Expenses reached $708000.0 in Q3 2025 per CRVS's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.2 million in Q3 2022 and bottomed at -$1.9 million in Q1 2023.
  • Average Change in Accured Expenses over 4 years is -$90666.7, with a median of $98000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: plummeted 401.04% in 2023, then skyrocketed 895.51% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2022, then surged by 42.37% to -$589000.0 in 2023, then grew by 16.81% to -$490000.0 in 2024, then soared by 244.49% to $708000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $708000.0 in Q3 2025, $1.1 million in Q2 2025, and $146000.0 in Q1 2025.